[ { "key": "X4VF6VCI", "version": 7, "library": { "type": "group", "id": 275567, "name": "FERTILITY PRESERVATION", "links": { "alternate": { "href": "https://www.zotero.org/groups/fertility_preservation", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/275567/items/X4VF6VCI", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/fertility_preservation/items/X4VF6VCI", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1993313, "username": "gyne", "name": "Karolina", "links": { "alternate": { "href": "https://www.zotero.org/gyne", "type": "text/html" } } }, "creatorSummary": "Somigliana E et al.", "parsedDate": "2014-07-10", "numChildren": 0 }, "data": { "key": "X4VF6VCI", "version": 7, "itemType": "magazineArticle", "title": "Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation.", "creators": [ { "creatorType": "author", "firstName": "Peccatori FA", "lastName": "Somigliana E" }, { "creatorType": "author", "firstName": "Martinelli F", "lastName": "Filippi F" }, { "creatorType": "author", "firstName": "Martinelli I", "lastName": "Raspagliesi F" } ], "abstractNote": "Abstract\nBACKGROUND:\n\nCompared with the general population, cancer patients have a higher risk of venous thromboembolism as well as arterial thrombotic events such as stroke, myocardial infarction and peripheral arterial embolism. Therefore a possible concern for women with malignancies undergoing ovarian stimulation for fertility preservation is the increased risk of venous or arterial thrombosis.\nMETHODS:\n\nIn this article, we revised current available literature on the risk of thrombosis in patients with cancer and in women undergoing ovarian stimulation, with the ultimate aim of drawing some indications for preventive measures.\nRESULTS:\n\nUnfortunately, there are no specific data on the risk of thrombosis in women with cancer undergoing ovarian stimulation for fertility preservation. However, the literature suggests that the cancer type and stage, surgery, and chemotherapy all influence the risk of venous and, possibly, arterial thrombosis. Reports of cases of ovarian stimulation in women without malignancies have shown that venous thrombosis rarely occurs unless a pregnancy is achieved, while arterial thrombosis can occur in the absence of pregnancy but is usually only associated with ovarian hyperstimulation syndrome (OHSS). OHSS increases the risk of thrombotic events, but only the early form of the syndrome is relevant for women undergoing fertility preservation.\nCONCLUSIONS:\n\nThe available evidence on the risks of thrombosis for women undergoing ovarian stimulation for fertility preservation due to a malignancy is reassuring. However the avoidance of the early form of OHSS in women preserving oocytes/embryos due to malignancy is crucial. For these cycles, we advocate the use of a regimen of ovarian stimulation with gonadotrophin releasing hormone (GnRH) antagonists using GnRH agonists to trigger ovulation, an approach that has been shown to markedly reduce the risk of OHSS. Antithrombotic prophylaxis should be administered only to selected subgroups of women such as those with other risk factors or those who do develop early OHSS.", "publicationTitle": "Hum Reprod Update.", "publisher": "", "place": "", "date": "2014 Jul 10.", "volume": "", "issue": "", "pages": "", "ISSN": "", "DOI": "", "citationKey": "", "url": "", "accessDate": "", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "n\n\n 1Infertility Unit, Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy dadosomigliana@yahoo.it.\n 2Fertility and Procreation Unit, Division of Gynaecologic Oncology, European Institute of Oncology, Milan, Italy.\n 3Infertility Unit, Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.\n 4Gynecologic Oncology Unit, Fondazione IRCCS National Cancer Institute, Milan, Italy.\n 5A. Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.", "tags": [ { "tag": "OHSS" }, { "tag": "cancer" }, { "tag": "fertility preservation" }, { "tag": "ovarian hyperstymulation" }, { "tag": "thrombosis" } ], "collections": [], "relations": {}, "dateAdded": "2014-07-29T11:42:31Z", "dateModified": "2014-07-29T11:42:31Z" } }, { "key": "MDW3ZSNR", "version": 6, "library": { "type": "group", "id": 275567, "name": "FERTILITY PRESERVATION", "links": { "alternate": { "href": "https://www.zotero.org/groups/fertility_preservation", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/275567/items/MDW3ZSNR", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/fertility_preservation/items/MDW3ZSNR", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1993313, "username": "gyne", "name": "Karolina", "links": { "alternate": { "href": "https://www.zotero.org/gyne", "type": "text/html" } } }, "creatorSummary": "Ottolina J et al.", "parsedDate": "2014-07", "numChildren": 0 }, "data": { "key": "MDW3ZSNR", "version": 6, "itemType": "magazineArticle", "title": "Reproductive function assessment after surgery plus chemotherapy for germ cell ovarian tumors (MOGCT): novel clues deriving from the field of fertility preservation.", "creators": [ { "creatorType": "author", "firstName": "Mangili G", "lastName": "Ottolina J" }, { "creatorType": "author", "firstName": "Vanni VS", "lastName": "Sigismondi C" }, { "creatorType": "author", "firstName": "Candiani M", "lastName": "Viganò P" } ], "abstractNote": "Abstract Germ cell ovarian tumors (malignant ovarian germ cell tumors - MOGCT) affect young women and are treated by surgery plus chemotherapy. It is well known that cytotoxic treatment may accelerate depletion of the primordial follicle pool leading to impaired fertility and premature menopause. Aim of this study is to identify patient candidates for fertility preservation strategies. We report our experience in preservation of fertility for four patients affected by MOGCT, referred to San Raffaele Hospital Oncofertility Unit. All patients received fertility sparing surgery plus platinum-based chemotherapy. Two patients were affected by mixed germ cell tumors and two by disgerminomas. After 24 months from the end of treatment, serum AMH levels have been measured. We report lower serum anti-Mullerian hormone (AMH) levels in our patients than in healthy general population as serum AMH levels were under the 25th age-specific percentiles. Fertility preservation, in terms of oocytes cryopreservation, was offered to those two patients with serum AMH levels predictive of significantly poor ovarian reserve (1st and 2nd patients). Using the gonadotropin releasing hormone (GnRH) antagonist protocol for ovarian stimulation, we obtained two and six oocytes, respectively. Therefore, serum AMH, as a marker of ovarian function, can improve the identification of patients that need to be referred to fertility preservation strategies.", "publicationTitle": "Gynecol Endocrinol.", "publisher": "", "place": "", "date": "2014 Jul", "volume": "18", "issue": "", "pages": "1-3", "ISSN": "", "DOI": "", "citationKey": "", "url": "", "accessDate": "", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "1Department of Obstetrics and Gynecology, Oncofertility Unit, San Raffaele Scientific Institute , Milan , Italy.", "tags": [ { "tag": "AMH" }, { "tag": "Anti - Mullerian Hormone" }, { "tag": "cytotoxic treatment" }, { "tag": "fertility preservation" }, { "tag": "germ cell ovarian tumors" }, { "tag": "infertility" }, { "tag": "oocytes cyopreservation" }, { "tag": "premature menopause" } ], "collections": [], "relations": {}, "dateAdded": "2014-07-29T11:38:56Z", "dateModified": "2014-07-29T11:38:56Z" } }, { "key": "5G29EEHP", "version": 5, "library": { "type": "group", "id": 275567, "name": "FERTILITY PRESERVATION", "links": { "alternate": { "href": "https://www.zotero.org/groups/fertility_preservation", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/275567/items/5G29EEHP", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/fertility_preservation/items/5G29EEHP", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1993313, "username": "gyne", "name": "Karolina", "links": { "alternate": { "href": "https://www.zotero.org/gyne", "type": "text/html" } } }, "creatorSummary": "Chang EM et al.", "parsedDate": "2014-06", "numChildren": 0 }, "data": { "key": "5G29EEHP", "version": 5, "itemType": "magazineArticle", "title": "In vitro maturation of human oocytes: Its role in infertility treatment and new possibilities.", "creators": [ { "creatorType": "author", "firstName": "Song HS", "lastName": "Chang EM" }, { "creatorType": "author", "firstName": "Lee WS", "lastName": " Lee DR" }, { "creatorType": "author", "firstName": "", "lastName": " Yoon TK" } ], "abstractNote": "IVM refers to the maturation of immature oocytes in culture after their recovery from small antral follicles at the stage prior to selection and dominance. IVM requires little or no FSH in vivo and has been proposed as an alternative to conventional IVF, since it reduces the primary adverse effects caused by controlled ovarian stimulation, including the ovarian hyperstimulation syndrome. Moreover, IVM is a promising option for cases for which no standard protocol is suitable, such as FSH resistance, contraindications for ovarian stimulatory drugs, and the need for urgent fertility preservation. Recently, IVM has been used in women with regular cycles and normal ovaries. However, the pregnancy rate following IVM is suboptimal compared with that of conventional IVF, indicating that further studies to optimize the protocol and the culture conditions are warranted.", "publicationTitle": "Clin Exp Reprod Med.", "publisher": "", "place": "", "date": "June 2014", "volume": "41", "issue": "2", "pages": "41-6", "ISSN": "", "DOI": "", "citationKey": "", "url": "", "accessDate": "", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "1Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University, Seoul, Korea.\n 2Department of Biomedical Science, College of Life Science, CHA University, Seoul, Korea.", "tags": [ { "tag": "fertility preservation" }, { "tag": "follicle culture" }, { "tag": "in vitro maturation" }, { "tag": "infertility" }, { "tag": "oocyte" } ], "collections": [], "relations": {}, "dateAdded": "2014-07-29T10:56:53Z", "dateModified": "2014-07-29T10:56:53Z" } }, { "key": "QREUU5VK", "version": 4, "library": { "type": "group", "id": 275567, "name": "FERTILITY PRESERVATION", "links": { "alternate": { "href": "https://www.zotero.org/groups/fertility_preservation", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/275567/items/QREUU5VK", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/fertility_preservation/items/QREUU5VK", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1993313, "username": "gyne", "name": "Karolina", "links": { "alternate": { "href": "https://www.zotero.org/gyne", "type": "text/html" } } }, "creatorSummary": "Razzano A et al.", "parsedDate": "2014-07-23", "numChildren": 0 }, "data": { "key": "QREUU5VK", "version": 4, "itemType": "magazineArticle", "title": "Fertility preservation program before ovarotoxic oncostatic treatments: role of the psychological support in managing emotional aspects.", "creators": [ { "creatorType": "author", "firstName": "Revelli A", "lastName": "Razzano A" }, { "creatorType": "author", "firstName": "Salvagno F", "lastName": "Delle Piane L" }, { "creatorType": "author", "firstName": "Randaccio S", "lastName": " Casano S" }, { "creatorType": "author", "firstName": "", "lastName": "Benedetto C" } ], "abstractNote": "Abstract Fertility preservation programs (FPPs) based on oocyte or ovarian tissue cryostorage may be offered to women facing oncostatic treatments at risk of precocious ovarian insufficiency. The way in which FPPs are presented to patients affects their decision to join them. We studied herein 48 young women to whom a FPP was proposed, aiming at clarifying the emotional aspects involved. A psychologist attended the consultations in which the FPP was offered to patients; at the end of the talk, a questionnaire was administered and a semi-structured interview was carried out. Finally, the STAI test was administered to measure trait (TAI) and state (SAI) anxiety, both immediately after consultation, and later on, when patients returned home. We observed that the possibility to join a FPP implied important emotional aspects, and that the presence of a psychologist was helpful to integrate technical information and emotions as well as to reduce trait and state anxiety levels. Our study suggests that the presence of a psychologist during the meeting in which a FPP is offered improves communication between doctors and patients, and helps these women to get a full awareness before choosing to join the FPP.", "publicationTitle": "Gynecol Endocrinol.", "publisher": "", "place": "", "date": "2014 Jul 23:", "volume": "", "issue": "", "pages": "1-3", "ISSN": "", "DOI": "", "citationKey": "", "url": "", "accessDate": "", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "Psychology Unit, Department of Gynecology and Obstetrics, S. Anna Hospital, University of Torino , Torino , Italy and.", "tags": [ { "tag": "female cancer" }, { "tag": "fertility preservation" }, { "tag": "iatrogenic infertility" }, { "tag": "oocyte cryostorage" }, { "tag": "ovarian tissue cryostorage" }, { "tag": "psycho-oncology" } ], "collections": [], "relations": {}, "dateAdded": "2014-07-29T10:25:28Z", "dateModified": "2014-07-29T10:25:28Z" } }, { "key": "Q2ZRXMH5", "version": 3, "library": { "type": "group", "id": 275567, "name": "FERTILITY PRESERVATION", "links": { "alternate": { "href": "https://www.zotero.org/groups/fertility_preservation", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/275567/items/Q2ZRXMH5", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/fertility_preservation/items/Q2ZRXMH5", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1993313, "username": "gyne", "name": "Karolina", "links": { "alternate": { "href": "https://www.zotero.org/gyne", "type": "text/html" } } }, "creatorSummary": "Vitek WS et al.", "parsedDate": "2014-07-17", "numChildren": 0 }, "data": { "key": "Q2ZRXMH5", "version": 3, "itemType": "journalArticle", "title": "Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis", "creators": [ { "creatorType": "author", "firstName": "Shayne M", "lastName": "Vitek WS" }, { "creatorType": "author", "firstName": " Han Y", "lastName": "Hoeger K" }, { "creatorType": "author", "firstName": "Fung C", "lastName": "Messing S" } ], "abstractNote": "Abstract\nOBJECTIVE:\n\nTo determine whether concurrent use of GnRH agonists with chemotherapy preserves ovarian function in women with breast cancer who did not use tamoxifen.\nDESIGN:\n\nSystematic review and meta-analysis.\nSETTING:\n\nUniversity-based hospitals.\nPATIENT(S):\n\nPremenopausal women with breast cancer treated with chemotherapy who did not receive tamoxifen.\nINTERVENTION(S):\n\nRandomization to concurrent GnRH agonists with chemotherapy or chemotherapy alone.\nMAIN OUTCOME MEASURE(S):\n\nOdds ratio (OR) of resumption of menses 1 year or more after chemotherapy.\nRESULT(S):\n\nSearches were conducted in PubMed, Scopus, Cochrane Trials Register, and the National Research Register through March 2014, and all randomized trials that reported resumption of menses 1 year or more after GnRH agonist with chemotherapy or chemotherapy alone among women with breast cancer who did not receive tamoxifen were included. Four studies were analyzed in the meta-analysis and included 252 patients (GnRH agonist with chemotherapy, n = 131; chemotherapy alone, n = 121). There was no significant difference in the rate of return of menses between the two groups (OR, 1.47; 95% confidence interval [0.60-3.62]). Heterogeneity among the trials was not significant (I2 = 16.6%).\nCONCLUSION(S):\n\nConcurrent GnRH agonists with chemotherapy may not preserve ovarian function in women with breast cancer. Furthermore, randomized data are limited regarding fertility after concurrent use of GnRH agonists with chemotherapy.\n\nCopyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.", "publicationTitle": "Fertil Steril.", "publisher": "", "place": "", "date": "17.07.2014", "volume": "", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "", "citationKey": "", "url": "", "accessDate": "", "PMID": "", "PMCID": "", "ISSN": "", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "GnRh agonist" }, { "tag": "breast cancer" }, { "tag": "fertility preservation" } ], "collections": [], "relations": {}, "dateAdded": "2014-07-24T11:04:09Z", "dateModified": "2014-07-24T11:04:09Z" } }, { "key": "I9VMT882", "version": 2, "library": { "type": "group", "id": 275567, "name": "FERTILITY PRESERVATION", "links": { "alternate": { "href": "https://www.zotero.org/groups/fertility_preservation", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/275567/items/I9VMT882", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/fertility_preservation/items/I9VMT882", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1993313, "username": "gyne", "name": "Karolina", "links": { "alternate": { "href": "https://www.zotero.org/gyne", "type": "text/html" } } }, "creatorSummary": "BĄCZKOWSKI TOMAZ", "parsedDate": "2011", "numChildren": 0 }, "data": { "key": "I9VMT882", "version": 2, "itemType": "magazineArticle", "title": "Profilaktyka niepłodności w chorobach onkologicznych", "creators": [ { "creatorType": "author", "firstName": "KURZAWA RAFAŁ", "lastName": "BĄCZKOWSKI TOMAZ" } ], "abstractNote": "Improvement of efficacy of the treatment in oncological diseases increase the population of cured but infertile people. It is a lot of limitation in the pharmacological and surgical prevention of fertility. The cryoprotection of the gametes and germinal tissues have important meaning in oncofertility. The progress in reproductive medicine and cryo­biology allows to protect better fertility among oncological patients. Sperm freezing and banking is the basic method by male. By woman oocyte/embryo cryopreservation are the options of fertility protection. Ovarian tissue cryopreservation and grafting is new, and more and more effective option of the treatment.", "publicationTitle": "ONKOFERTILITY", "publisher": "", "place": "", "date": "2011", "volume": "1", "issue": "", "pages": "", "ISSN": "", "DOI": "", "citationKey": "", "url": "", "accessDate": "", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "PL", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "FERTILITY" }, { "tag": "NEOPLASM" }, { "tag": "ONKOFERTILITY" } ], "collections": [], "relations": {}, "dateAdded": "2014-07-24T08:23:12Z", "dateModified": "2014-07-24T08:23:12Z" } } ]